tiprankstipranks
Trending News
More News >
Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN

Newron Pharmaceuticals SpA (NWRN) AI Stock Analysis

Compare
0 Followers

Top Page

CH

Newron Pharmaceuticals SpA

(OTC:NWRN)

Rating:68Neutral
Price Target:
CHF8.50
▲(16.76%Upside)
Newron Pharmaceuticals SpA's overall stock score is driven by significant revenue growth and improved profitability, providing a strong foundation. However, high financial leverage and negative cash flow pose risks that could impact long-term stability. The stock's technical indicators show a positive trend, reflecting potential short-term gains. Valuation suggests it is attractively priced, but the lack of a dividend could be a drawback for some investors.

Newron Pharmaceuticals SpA (NWRN) vs. iShares MSCI Switzerland ETF (EWL)

Newron Pharmaceuticals SpA Business Overview & Revenue Model

Company DescriptionNewron Pharmaceuticals SpA (NWRN) is a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous systems. Headquartered in Bresso, Italy, the company is engaged in the research and development of pharmaceutical products targeting neurological and psychiatric disorders. Newron's core product pipeline includes innovative treatments for conditions such as Parkinson's disease, schizophrenia, and rare diseases characterized by pain and inflammation.
How the Company Makes MoneyNewron Pharmaceuticals SpA primarily generates revenue through the development and commercialization of its proprietary pharmaceutical products. The company's revenue model is based on securing licensing agreements and partnerships with larger pharmaceutical companies for the development and marketing of its drug candidates. These collaborations often involve upfront payments, milestone payments upon achieving specific development or regulatory milestones, and royalties on sales of successfully commercialized products. Additionally, Newron may receive research grants and funding to support its drug development programs, contributing to its overall revenue.

Newron Pharmaceuticals SpA Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
6.97M9.06M6.09M5.76M5.26M7.04M
Gross Profit
6.97M9.06M6.09M5.76M4.96M5.61M
EBIT
-15.01M-11.63M-13.30M-12.36M-18.07M-20.90M
EBITDA
-14.88M-11.83M-13.32M-12.31M-17.99M-20.85M
Net Income Common Stockholders
-18.83M-16.22M-17.49M-14.90M-21.00M-20.21M
Balance SheetCash, Cash Equivalents and Short-Term Investments
39.16M12.60M22.77M34.59M31.25M39.16M
Total Assets
60.29M25.87M37.20M50.49M51.20M60.29M
Total Debt
16.89M48.41M45.66M43.08M26.34M16.89M
Net Debt
-5.17M42.08M32.24M18.06M13.13M-5.17M
Total Liabilities
23.49M55.77M51.23M47.38M33.95M23.49M
Stockholders Equity
36.80M-29.91M-14.03M3.11M17.25M36.80M
Cash FlowFree Cash Flow
-13.38M-10.15M-11.11M-11.46M-15.62M-22.03M
Operating Cash Flow
-13.37M-10.14M-11.09M-11.45M-15.59M-21.98M
Investing Cash Flow
5.27M3.25M-317.00K8.42M-616.00K-932.00K
Financing Cash Flow
8.28M-192.00K-186.00K14.83M7.37M17.34M

Newron Pharmaceuticals SpA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.28
Price Trends
50DMA
7.45
Negative
100DMA
8.42
Negative
200DMA
8.20
Negative
Market Momentum
MACD
-0.07
Positive
RSI
41.47
Neutral
STOCH
3.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:NWRN, the sentiment is Negative. The current price of 7.28 is below the 20-day moving average (MA) of 7.78, below the 50-day MA of 7.45, and below the 200-day MA of 8.20, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.47 is Neutral, neither overbought nor oversold. The STOCH value of 3.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:NWRN.

Newron Pharmaceuticals SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
CHF557.64M7.24
32.30%631.04%
68
Neutral
CHF145.52M10.37
450.19%
53
Neutral
$5.25B3.24-45.38%2.81%16.79%-0.06%
51
Neutral
CHF382.17M
11.61%-356.20%
50
Neutral
CHF121.12M-40.40%-66.82%4.14%
44
Neutral
$127.16M2.58-93.91%-62.17%-166.33%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:NWRN
Newron Pharmaceuticals SpA
7.32
-2.72
-27.09%
CH:MOLN
Molecular Partners AG
3.03
-0.64
-17.44%
CH:BSLN
Basilea Pharmaceutica
46.35
3.90
9.19%
CH:IDIA
Idorsia Ltd
2.00
-0.23
-10.31%
CH:SANN
Santhera Pharmaceuticals Holding
13.16
3.54
36.80%

Newron Pharmaceuticals SpA Corporate Events

Newron Pharmaceuticals Advances Phase III Program for Schizophrenia Treatment
May 12, 2025

Newron Pharmaceuticals has received approval for its pivotal Phase III development program ENIGMA-TRS, which will evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). This program, consisting of two studies, aims to meet regulatory requirements for marketing authorization in major markets like the USA and Europe. The approval marks a significant step for Newron, potentially enhancing its market position by addressing the unmet medical need for effective TRS treatments. The studies will assess the efficacy, tolerability, and safety of Evenamide, with patient recruitment starting immediately and results expected in late 2026.

Newron Pharmaceuticals Advances Phase-III Trials for Schizophrenia Treatment
May 12, 2025

Newron Pharmaceuticals announced the approval of its pivotal Phase-III development program ENIGMA-TRS, which includes two studies to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The studies, ENIGMA-TRS 1 and ENIGMA-TRS 2, aim to address the unmet medical need for effective treatments in TRS patients by targeting the glutamatergic system, offering a new therapeutic option for those who do not respond adequately to current antipsychotics.

New Leadership and Strategic Financial Moves at Newron Pharmaceuticals
Apr 23, 2025

Newron Pharmaceuticals announced the election of Dr. Chris Martin as the new Chairman of the Board during their 2025 General Meeting. The meeting also extended a capital increase until 2028, although some agenda items were not voted on due to a lack of quorum. This leadership change and financial strategy adjustment may influence Newron’s future operations and strategic direction, especially in the context of their ongoing drug development efforts.

Newron Pharmaceuticals Reports Strong 2024 Results and Strategic Growth Plans for 2025
Apr 1, 2025

Newron Pharmaceuticals reported significant progress in 2024, highlighted by promising data from studies on Evenamide, a potential treatment for schizophrenia. The company secured strategic licensing agreements with EA Pharma and Myung In Pharm, enhancing its market presence in Asia and supporting its upcoming Phase III study. With a net profit of EUR 15.8 million, Newron is poised for further growth in 2025, driven by its robust financial position and strategic partnerships.

Newron Pharmaceuticals Reports Profit and Strategic Advances in 2024
Apr 1, 2025

Newron Pharmaceuticals reported a net profit of EUR 15.8 million for 2024, a significant turnaround from the previous year’s loss, driven by licensing revenues from agreements with EA Pharma/Eisai Group and Myung In Pharm. The company has strengthened its financial position and expanded its market reach through strategic partnerships and capital measures, positioning itself for further growth in 2025 with plans to advance Evenamide’s development and potentially register its shares in the USA.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.